Relmada Therapeutics Inc. (RLMD)
0.26
0.00 (0.00%)
At close: Mar 03, 2025, 3:59 PM
0.24
-5.22%
After-hours: Mar 03, 2025, 06:03 PM EST
No 1D chart data available
| Bid | 0.24 |
| Market Cap | 7.69M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -86.49M |
| EPS (ttm) | -2.86 |
| PE Ratio (ttm) | -0.09 |
| Forward PE | -0.27 |
| Analyst | Hold |
| Ask | 0.26 |
| Volume | 442,617 |
| Avg. Volume (20D) | 1,778,417 |
| Open | 0.26 |
| Previous Close | 0.26 |
| Day's Range | 0.24 - 0.26 |
| 52-Week Range | 0.24 - 7.22 |
| Beta | 0.50 |
About RLMD
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 20, 2014
Employees 20
Stock Exchange NASDAQ
Ticker Symbol RLMD
Website https://www.relmada.com
Analyst Forecast
According to 4 analyst ratings, the average rating for RLMD stock is "Hold." The 12-month stock price forecast is $1, which is an increase of 292.16% from the latest price.
Buy 25.00%
Hold 50.00%
Sell 25.00%
2 months ago
-9.03%
Relmada Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
5 months ago
+13.53%
Relmada Therapeutics shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $3.5 to $13.
